NEW
YORK, June 18, 2024 /PRNewswire/ -- The global
endocrinology drugs market size is estimated to grow by
USD 36.83 mn from 2024-2028,
according to Technavio. The market is estimated to grow at a CAGR
of over 7.45% during the forecast
period. Increase in incidence of endocrine
disorders is driving market growth, with a trend
towards association between obesity and endocrine disorders.
However, patent expiry of major endocrinology drugs
poses a challenge. Key market players include Abbott
Laboratories, Acerus Pharmaceuticals Corp., Ascendis Pharma AS,
Bayer AG, Beta Cell NV, Biocon Ltd., Eli Lilly and Co., Endo
International Plc, F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc,
Hanmi Pharm Co. Ltd., Ipsen Pharma, Merck and Co. Inc., Novartis
AG, Novo Nordisk AS, Oramed Pharmaceuticals Inc., Pfizer Inc.,
Sanofi SA, Takeda Pharmaceutical Co. Ltd., and VeroScience LLC.
Get a detailed analysis on regions, market
segments, customer landscape, and companies - Click for the
snapshot of this report
Forecast
period
|
2024-2028
|
Base Year
|
2023
|
Historic
Data
|
2018 - 2022
|
Segment
Covered
|
Therapy Area (Diabetes
drugs, hGH, Thyroid hormone disorders, and Others), Distribution
Channel (Hospital pharmacies, Retail pharmacies, and Online
pharmacies), and Geography (North America, Europe, Asia, and Rest
of World (ROW))
|
Region
Covered
|
North America, Europe,
Asia, and Rest of World (ROW)
|
Key companies
profiled
|
Abbott Laboratories,
Acerus Pharmaceuticals Corp., Ascendis Pharma AS, Bayer AG, Beta
Cell NV, Biocon Ltd., Eli Lilly and Co., Endo International Plc, F.
Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Hanmi Pharm Co. Ltd.,
Ipsen Pharma, Merck and Co. Inc., Novartis AG, Novo Nordisk AS,
Oramed Pharmaceuticals Inc., Pfizer Inc., Sanofi SA, Takeda
Pharmaceutical Co. Ltd., and VeroScience LLC
|
Key Market Trends Fueling Growth
The obesity epidemic is linked to a rise in endocrine disorders,
including diabetes, hypothyroidism, and PCOS. These conditions can
cause or result from obesity. Endocrine disorders related to
obesity can often be managed through weight loss. Obesity, type-2
diabetes mellitus, and thyroid diseases are common co-occurring
conditions. Hypothyroidism is the most frequent causative factor,
leading to reduced metabolic efficiency, increased water retention,
and decreased lipolysis. Sedentary lifestyles, smoking, and dietary
changes contribute to both obesity and endocrine disorders. This
association drives the growth of the global endocrinology drugs
market.
The endocrinology drugs market is experiencing significant
growth due to the increasing prevalence of endocrine disorders such
as diabetes, hypothyroidism, and hyperthyroidism. The market is
driven by the development of new treatments and therapies,
including synthetic hormones and insulin derivatives. Hormone
replacement therapies are also gaining popularity for the treatment
of menopausal symptoms. Additionally, the use of biologics and
peptide-based drugs is on the rise, as they offer more targeted and
effective treatments. The market is competitive, with major players
investing in research and development to bring innovative products
to market. The use of technology, such as telemedicine and digital
health solutions, is also transforming the way endocrinology drugs
are delivered and administered. Overall, the endocrinology drugs
market is expected to continue growing in the coming
years.
Research report provides comprehensive data on
impact of trend. For more details- Download a Sample
Report
Market Challenges
- Endocrinology drugs, such as PREMPRO and PREMPHASE, have been
available since the late 1990s. However, patent expiry for many of
these medications, including Lantus and Humalog, has led to the
entry of generic alternatives and decreased market share for
branded drugs. Manufacturers employ strategies like clustered
patents and patent litigations to delay generic entry. Post-patent
expiry, biosimilars have improved treatment affordability and
accessibility for endocrine disorders, but face payer resistance.
Notable drugs with upcoming patent expiry include BYETTA, Victoza,
APIDRA, and JANUVIA.
- The Endocrinology Drugs Market faces several challenges in the
reproduction and discovery of new treatments. These include the
complexity of endocrine systems and disorders, the need for
personalized medicine, and the high cost of research and
development. Additionally, regulatory requirements and ethical
considerations add to the challenges. For instance, the discovery
of new hormones and their receptors is a complex process.
Furthermore, personalized medicine requires a deep understanding of
individual patient needs, which can be challenging to achieve.
Lastly, the high cost of research and development, coupled with
regulatory hurdles, can make bringing new endocrinology drugs to
market a lengthy and expensive process.
For more insights on driver and
challenges - Download a Sample Report
Segment Overview
This endocrinology drugs market report extensively covers market
segmentation by
- Therapy Area
- 1.1 Diabetes drugs
- 1.2 hGH
- 1.3 Thyroid hormone disorders
- 1.4 Others
- Distribution Channel
- 2.1 Hospital pharmacies
- 2.2 Retail pharmacies
- 2.3 Online pharmacies
- Geography
- 3.1 North America
- 3.2 Europe
- 3.3 Asia
- 3.4 Rest of World (ROW)
1.1 Diabetes drugs- The Endocrinology Drugs Market
is experiencing steady growth due to the increasing prevalence of
diabetes and other endocrine disorders. Key players in this market
include Sanofi, Novo Nordisk, and Eli Lilly. They offer treatments
for diabetes, thyroid disorders, and growth hormone deficiencies.
Market expansion is driven by rising demand for effective and
affordable medicines. Collaborations and acquisitions are common
strategies to enhance product portfolios and gain a competitive
edge.
For more information on market segmentation with
geographical analysis including forecast (2024-2028) and historic
data (2018 - 2022) - Download a Sample Report
Research Analysis
The Endocrinology Drugs Market encompasses a range of
pharmaceutical products designed to treat disorders of the
endocrine system. These disorders can include hormonal imbalances
resulting from conditions affecting the pancreas, thyroid,
parathyroid, adrenals, testes, ovaries, pituitary, and
hypothalamus. The market includes drugs that target amines,
steroids, peptides, and proteins, playing crucial roles in
metabolism, reproduction, and the regulation of various bodily
functions. Endocrinologists frequently prescribe medications such
as Levothyroxine Sodium Injection for thyroid disorders,
Teneligliptin, Pioglitazone, and Metformin for managing Type 2
diabetes. Unhealthy lifestyle characteristics, including work
stress and weight gain, can contribute to hormonal imbalances and
the need for these medications. Cholesterol levels can also be
affected by endocrine disorders, making the development of
effective treatments a priority in this market.
Market Research Overview
The Endocrinology Drugs Market encompasses a variety of
treatments for disorders related to the endocrine system. These
conditions include diabetes, thyroid disorders, pituitary
disorders, and hormonal imbalances. The market is driven by the
rising prevalence of endocrine disorders and the increasing demand
for effective and safe treatments. The market is segmented based on
drug classes, such as insulins, oral antidiabetics, thyroid
hormones, and growth hormones. The market is also influenced by
factors like regulatory policies, technological advancements, and
pricing trends. The use of advanced technologies like biosimilars
and generic drugs is expected to increase competition in the
market. The market is projected to grow significantly in the
forecast period due to the increasing burden of endocrine disorders
and the development of new and innovative treatments.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
- Therapy Area
-
- Diabetes Drugs
- HGH
- Thyroid Hormone Disorders
- Others
- Distribution Channel
-
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Geography
-
- North America
- Europe
- Asia
- Rest Of World (ROW)
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory
company. Their research and analysis focuses on emerging market
trends and provides actionable insights to help businesses identify
market opportunities and develop effective strategies to optimize
their market positions.
With over 500 specialized analysts, Technavio's report library
consists of more than 17,000 reports and counting, covering 800
technologies, spanning across 50 countries. Their client base
consists of enterprises of all sizes, including more than 100
Fortune 500 companies. This growing client base relies on
Technavio's comprehensive coverage, extensive research, and
actionable market insights to identify opportunities in existing
and potential markets and assess their competitive positions within
changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/endocrinology-drugs-market-size-is-set-to-grow-by-usd-36-83-billion-from-2024-2028--increase-in-incidence-of-endocrine-disorders-to-boost-the-market-growth-technavio-302174097.html
SOURCE Technavio